Skip to main content

Research Repository

Advanced Search

All Outputs (96)

Emulating the EPIC trial using VetCompass primary-care data: causal effects of pimobendan in UK dogs with grade IV/VI heart murmurs (2025)
Journal Article
Pegram, C., Diaz-Ordaz, K., Brodbelt, D. C., Chang, Y.-M., Boswood, A., Wilshaw, J., Reep, C. A. T., Balling, S., Sahota, J., Church, D. B., & O’Neill, D. G. (2025). Emulating the EPIC trial using VetCompass primary-care data: causal effects of pimobendan in UK dogs with grade IV/VI heart murmurs. PLoS ONE, 20(6), e0325695. https://doi.org/10.1371/journal.pone.0325695

Improvement in short-term outcome over time, in a single center embarking on a canine mitral valve repair program using a structured multidisciplinary approach (2025)
Journal Article
Brockman, D., Greensmith, T., Rossanese, M., Young, A., Carey, S., Boswood, A., Stathopoulou, T., Jimenez, C., & Cross, N. (2025). Improvement in short-term outcome over time, in a single center embarking on a canine mitral valve repair program using a structured multidisciplinary approach. Veterinary Surgery, https://doi.org/10.1111/vsu.14229

Objective: To describe a structured approach to the development of a mitral valve repair (MVR) program for dogs with myxomatous mitral valve disease (MMVD) and to document the change in short term outcome over time. Study design: Clinical prospective... Read More about Improvement in short-term outcome over time, in a single center embarking on a canine mitral valve repair program using a structured multidisciplinary approach.

Effect of a specially formulated diet on progression of heart enlargement in dogs with subclinical degenerative mitral valve disease (2023)
Journal Article
Oyama, M., Scansen, B., Boswood, A., Goldfeder, G., Rosenthal, S., Cober, R., LaFauci, K., Friese, R., Gomes, M., Chang, Y., & Li, Q. (2023). Effect of a specially formulated diet on progression of heart enlargement in dogs with subclinical degenerative mitral valve disease. Journal of Veterinary Internal Medicine, https://doi.org/10.1111/jvim.16796

BackgroundPrevious studies in dogs with degenerative mitral valve disease (DMVD) have identified altered myocardial energy metabolism and oxidation, which might contribute to cardiac hypertrophy. Diets rich in medium chain fatty acids and antioxidant... Read More about Effect of a specially formulated diet on progression of heart enlargement in dogs with subclinical degenerative mitral valve disease.

Evidence of altered fatty acid metabolism in dogs with naturally occurring valvular heart disease and congestive heart failure (2022)
Journal Article
Wilshaw, J., Boswood, A., Chang, Y., Sands, C., Camuzeaux, S., Lewis, M., Xia, D., & Connolly, D. (2022). Evidence of altered fatty acid metabolism in dogs with naturally occurring valvular heart disease and congestive heart failure. Metabolomics, 18(6), https://doi.org/10.1007/s11306-022-01887-7

Introduction Myxomatous mitral valve disease (MMVD) is the most common cardiac condition in adult dogs. The disease progresses over several years and affected dogs may develop congestive heart failure (HF). Research has shown that myocardial metaboli... Read More about Evidence of altered fatty acid metabolism in dogs with naturally occurring valvular heart disease and congestive heart failure.

Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease (2021)
Journal Article
Wilshaw, J., Rosenthal, S., Wess, G., Dickson, D., Bevilacqua, L., Dutton, E., Deinert, M., Abrantes, R., Schneider, I., Oyama, M., Gordon, S., Elliott, J., Xia, D., & Boswood, A. (2021). Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease. Journal of Veterinary Internal Medicine, 35(2), 755-770. https://doi.org/10.1111/jvim.16083

Background Treatment is indicated in dogs with preclinical degenerative mitral valve disease (DMVD) and cardiomegaly (stage B2). This is best diagnosed using echocardiography; however, relying upon this limits access to accurate diagnosis. Objectives... Read More about Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease.

The effect of myxomatous mitral valve disease severity on packed cell volume in dogs (2021)
Journal Article
Wilshaw, J., Stein, M., Lotter, N., Elliott, J., & Boswood, A. (2021). The effect of myxomatous mitral valve disease severity on packed cell volume in dogs. Journal of Small Animal Practice, 62(6), 428-436. https://doi.org/10.1111/jsap.13308

Objectives The aim of this study was to examine whether associations between disease severity and packed cell volume exist in dogs with myxomatous mitral valve disease. Materials and Methods Data were selected from 289 dogs that had been examined at... Read More about The effect of myxomatous mitral valve disease severity on packed cell volume in dogs.

Risk indictors in cats with preclinical hypertrophic cardiomyopathy: a prospective cohort study (2020)
Journal Article
Ironside, V. A., Tricklebank, P. R., & Boswood, A. (2020). Risk indictors in cats with preclinical hypertrophic cardiomyopathy: a prospective cohort study. Journal of Feline Medicine and Surgery, 1098612X2093865

Objectives
This study aimed to identify indicators of the risk of progression of preclinical hypertrophic cardiomyopathy (HCM).

Methods
This was a prospective cohort study following a population of cats with preclinical HCM. Cats serially underw... Read More about Risk indictors in cats with preclinical hypertrophic cardiomyopathy: a prospective cohort study.

Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study (2020)
Journal Article
Boswood, A., Gordon, S. G., Häggström, J., Vanselow, M., Wess, G., Stepien, R. L., Oyama, M. A., Keene, B. W., Bonagura, J., MacDonald, K. A., Patteson, M., Smith, S., Fox, P. R., Sanderson, K., Woolley, R., Szatmári, V., Menaut, P., Church, W. M., O'Sullivan, M. L., Jaudon, J.-P., …Watson, P. (2020). Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study. Journal of Veterinary Internal Medicine, https://doi.org/10.1111/jvim.15753

The Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical myxomatous mitral valve disease (EPIC) study monitored dogs with myxomatous mitral valve disease (MMVD) as they developed congestive heart failure (CHF).

Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom (2019)
Journal Article
Mattin, M. J., Brodbelt, D. C., Church, D. B., & Boswood, A. (2019). Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom. Journal of Veterinary Internal Medicine, https://doi.org/10.1111/jvim.15390

Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study (2018)
Journal Article
Boswood, A., Gordon, S. G., Häggström, J., Wess, G., Stepien, R. L., Oyama, M. A., Keene, B. W., Bonagura, J. D., MacDonald, K. A., Patteson, M., Smith, S., Fox, P. R., Sanderson, K., Woolley, R., Szatmári, V., Menaut, P., Church, W. M., O'Sullivan, M. L., Jaudon, J. P., Kresken, J.-G., …Watson, P. (2018). Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study. Journal of Veterinary Internal Medicine, 32(1), 72-85. https://doi.org/10.1111/jvim.14885

Background: Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described.

Objectives: To investigate the effect of pimobenda... Read More about Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.

Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study (2017)
Journal Article
Hezzell, M. J., Boswood, A., Lopez-Alvarez, J., Lotter, N. S., & Elliott, J. (2017). Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study. Journal of Veterinary Cardiology, 19(4), 325-328. https://doi.org/10.1016/j.jvc.2017.06.001

Spironolactone improves outcome in dogs with advanced myxomatous mitral valve disease (MMVD). Its efficacy in preclinical MMVD is unknown. The hypothesis was the administration of spironolactone to dogs with compensated MMVD demonstrating risk factor... Read More about Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study.

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study - A Randomized Clinical Trial (2016)
Journal Article
Boswood, A., Haggstrom, J., Gordon, S. G., Wess, G., Stepien, R. L., Oyama, M. A., Keene, B. W., Bonagura, J. D., MacDonald, K. A., Patteson, M., Smith, S., Fox, P. R., Sanderson, K., Woolley, R., Szatmari, V., Menaut, P., Church, W. M., O'Sullivan, M. L., Jaudon, J. P., Kresken, J. G., …Watson, P. (2016). Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study - A Randomized Clinical Trial. Journal of Veterinary Internal Medicine, 30(6), 1765-1779. https://doi.org/10.1111/jvim.14586

Differentiation of Cardiac from Noncardiac Pleural Effusions in Cats using Second-Generation Quantitative and Point-of-Care NT-proBNP Measurements (2016)
Journal Article
Hezzell, M. J., Rush, J. E., Humm, K. R., Rozanski, E. A., Sargent, J., Connolly, D. J., Boswood, A., & Oyama, M. A. (2016). Differentiation of Cardiac from Noncardiac Pleural Effusions in Cats using Second-Generation Quantitative and Point-of-Care NT-proBNP Measurements. Journal of Veterinary Internal Medicine, 30(2), 536-542. https://doi.org/10.1111/jvim.13831

Prevalence of and risk factors for degenerative mitral valve disease in dogs attending primary-care veterinary practices in england (2015)
Journal Article
Mattin, M. J., Boswood, A., Church, D. B., Lopez-Alvarez, J., McGreevy, P. D., O'Neill, D. G., Thomson, P. C., & Brodbelt, D. C. (2015). Prevalence of and risk factors for degenerative mitral valve disease in dogs attending primary-care veterinary practices in england. Journal of Veterinary Internal Medicine, 29(3), 847-854. https://doi.org/10.1111/jvim.12591

Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Myxomatous Mitral Valve Disease Receiving Pimobendan or Benazepril: The QUEST Study. (2013)
Journal Article
Haggstrom, J. H., Boswood, A., O'Grady, M., Joens, O., Smith, S., Swift, S., Borgarelli, M., Gavaghan, B., Kresken, J. G., Patteson, M., Ablad, B., Bussadori, C., Glaus, T., Kovacevic, A., Rapp, M., Santilli, R. A., Tidholm, A., Eriksson, A., Belanger, M. C., Deinert, M., …DiFruscia, R. (2013). Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Myxomatous Mitral Valve Disease Receiving Pimobendan or Benazepril: The QUEST Study. Journal of Veterinary Internal Medicine, 27(6), 1441-1451. https://doi.org/10.1111/jvim.12181